Gilead Sciences SEC filings, summarized
We read every Gilead Sciences 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track GILD in your inbox
Add Gilead Sciences to your watchlist — free, every morning.
Recent filings
Gilead filed exhibits re: an acquisition — Agreement & Plan of Merger (dated Feb 22, 2026) among Gilead,…
Gilead filed exhibits re: an acquisition — Agreement & Plan of Merger (dated Feb 22, 2026) among Gilead, Arcellx and Ravens Sub; Form of Tender & Support…
Feb 23, 2026: $GILD and $ACLX announced they signed a Merger Agreement and the FDA accepted the BLA for…
Feb 23, 2026: $GILD and $ACLX announced they signed a Merger Agreement and the FDA accepted the BLA for anito‑cel (BCMA ddCAR) for relapsed/refractory…
BREAKING: $GILD strikes deal to buy Arcellx — tender offer $115/.share + 1 CVR (up to $5 more if anito‑cel…
BREAKING: $GILD strikes deal to buy Arcellx — tender offer $115/.share + 1 CVR (up to $5 more if anito‑cel hits $6B in cumulative sales by 12/31/2029).…
Gilead ($GILD) filed a Form 8‑K on Feb 10, 2026: Exhibit 99.1 = press release (Feb 10, 2026) and Exhibit…
Gilead ($GILD) filed a Form 8‑K on Feb 10, 2026: Exhibit 99.1 = press release (Feb 10, 2026) and Exhibit 104 = Inline XBRL cover page. Filing signed by CFO…
Gilead ($GILD) announced Q4 & FY 2025 results on Feb 10, 2026; press release is filed as Exhibit 99.1 to…
Gilead ($GILD) announced Q4 & FY 2025 results on Feb 10, 2026; press release is filed as Exhibit 99.1 to the 8‑K — see Exhibit 99.1 for full financial…